Back to Search
Start Over
CUR-N399, a PI4KB inhibitor, for the treatment of Enterovirus A71 infection.
- Source :
-
Antiviral research [Antiviral Res] 2023 Oct; Vol. 218, pp. 105713. Date of Electronic Publication: 2023 Aug 31. - Publication Year :
- 2023
-
Abstract
- Over the years, the hand, foot and mouth disease (HFMD) has sparked epidemics across many countries which mainly affected young children. While symptoms are usually mild, severe complications may arise, and some even lead to death. Such concerns, coupled with the lack of approved vaccines and antivirals to date, create an urgency in the identification of safe therapeutics against HFMD. The disease is mainly transmitted by enteroviruses like enterovirus A71 (EV-A71). Essential for enterovirus replication is the host protein, PI4KB. In this study, we investigate the antiviral efficacy of a novel PI4KB inhibitor, CUR-N399. We found that CUR-N399 displayed broad-spectrum antiviral activity against picornaviruses in cell culture models. Using a suckling mouse model of lethal EV-A71 infection, CUR-N399 was found to be well-tolerated, promote survival and reduce viral titre in mice organs. Together, these support the discovery of CUR-N399 as an antiviral against EV-A71 and potentially other closely related viruses.<br />Competing Interests: Declaration of competing interest CUR-N399 is covered in patent/patent applications owned by Curovir AB (J.W. and G.A.). D.H.J.C., T.Y., Y.H.W and J.J.H.C. declare no potential conflict of interest.<br /> (Copyright © 2023 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1872-9096
- Volume :
- 218
- Database :
- MEDLINE
- Journal :
- Antiviral research
- Publication Type :
- Academic Journal
- Accession number :
- 37657668
- Full Text :
- https://doi.org/10.1016/j.antiviral.2023.105713